Skip to content
MarketScale
‹ Back to IndustriesSciences

China Is Showing No Signs of Slowing Down Space Exploration

Blaine Curcio is the Founder of Orbital Gateway Consulting and a foremost expert on the Chinese space sector. His podcast, Dongfang Hour, provides essential information on the Chinese space program from Chinese sources. Space to Grow’s Chris Blackerby and Charity Weeden recently got the opportunity to chat with Blaine and talk about all things…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · Blaine CurcioChina Space ProgramDongfang HourSpace Economy
Share

Key takeaways

01

Blaine Curcio is the Founder of Orbital Gateway Consulting and a foremost expert on the Chinese space sector.

02

His podcast, Dongfang Hour, provides essential information on the Chinese space program from Chinese sources.

03

Space to Grow’s Chris Blackerby and Charity Weeden recently got the opportunity to chat with Blaine and talk about all things…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

Blaine Curcio is the Founder of Orbital Gateway Consulting and a foremost expert on the Chinese space sector. His podcast, Dongfang Hour, provides essential information on the Chinese space program from Chinese sources. Space to Grow’s Chris Blackerby and Charity Weeden recently got the opportunity to chat with Blaine and talk about all things space exploration in China.

Is the Chinese space program shrouded in mystery, or is this a perception issue in the West? Weeden wanted to know the facts from the cloud of misinformation.

“One thing I hear a lot is this assumption that the Chinese government is omnipotent,” Curcio said. “If they say, for example, build us a 5,000 satellite LEO broadband constellation, there’s an impression that will just get done tomorrow, and there are no questions asked; at the end of the day, that’s an oversimplification in the sense that you do have in this system a lot of different competing forces, factions, and entities that have their own interests. And you have incentives that don’t make it that easy.”

For the past decade, China’s made a significant investment in space, technology, resources, and funding. And they show no signs of slowing down with ambitious plans over the next several years. They plan to complete the International Lunar Research Station in the next fifteen years. “If we look at plans like that, that seems extremely ambitious,” Curcio said. “And I think the space station has some interesting potential to expand in the medium to long-term.”

One difference between the Chinese space program and The United States is the coordination of efforts. The US tends to lead national efforts run by NASA, and China takes a more siloed approach with various companies working with local and provincial governments. Without a top-down coordinated attempt, Curcio said some of China’s plans for space could experience difficulties.

More in This Series

The Infrastructure Available to the Commercial Space Industry will Impact Affordability of Launches

The Impact of the Russian ASAT Tests

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

CB
Chris Blackerby

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers has terminated its agreement with Cellares, which raises concerns about the standardized capacity for cell therapy production. This decision highlights the importance of aligning manufacturing processes with production capabilities, rather than merely focusing on the availability of factory slots.

  • 01Bristol Myers has terminated its agreement with Cellares, affecting cell therapy capacity.
  • 02Aligning process fit with production capabilities is crucial for cell therapy success.
  • 03Factory slots alone are not sufficient to ensure supply plans in cell therapy production.

Aug 26, 2026

Argonne’s AI agents push materials R&D toward days-long cycles

Argonne’s AI agents push materials R&D toward days-long cycles

Argonne National Laboratory is utilizing AI agents to accelerate materials R&D cycles, reducing the time span to just a few days. This advancement hinges on prioritizing dataflow and security over larger AI models. The novel approach aims to streamline processes and enhance the efficiency of research and development activities.

  • 01Argonne National Laboratory is using AI agents to significantly shorten materials R&D cycles.
  • 02The focus of procurement has shifted to dataflow and security rather than larger AI models.
  • 03Improved workflows facilitate more efficient research and development efforts.

Aug 25, 2026

Cancer diagnostics growth is forcing labs to budget for data, not just instruments

Cancer diagnostics growth is forcing labs to budget for data, not just instruments

The growth in cancer diagnostics is prompting laboratories to allocate budgets not only for instruments but also for data management. Market forecasts predict an increase in the cancer diagnostics market from $29.86 billion in 2026 to $44.92 billion by 2031. Staffing is identified as a significant operational constraint according to industry insights.

  • 01Cancer diagnostics market is expected to grow from $29.86 billion in 2026 to $44.92 billion by 2031.
  • 02Laboratories are increasingly required to budget for data management alongside instruments.
  • 03Staffing is a major operational constraint in the growth of cancer diagnostics.

Aug 24, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512